DRUGS giant GlaxoSmithKline will assume full control of protein technology company Cellzome following an offer worth £61m for the shares it does not already own.
Glaxo and Cellzome, which has laboratories in Cambridge and Heidelberg, already have two active early stage research collaborations.
